Trial Profile
An Open Label, Non Comparative, Prospective Pilot Study, to Assess the Efficacy and Safety of the Probiotic E. Coli Strain M17 on Patients With GERD
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Escherichia coli M17 (Primary)
- Indications Gastro-oesophageal reflux
- Focus Registrational; Therapeutic Use
- Sponsors The BioBalance Corporation
- 26 Jan 2015 Status changed from not yet recruiting to completed, as reported by ClinicalTrials.gov.
- 19 May 2014 New trial record